MBio Diagnostics, Inc. Announces Sue Sutton-Jones Joins as VP of Regulatory Affairs and Quality Assuranc

BOULDER, CO--(Marketwired - April 09, 2013) -

MBio Diagnostics, Inc. announced today that it has expanded its leadership team with the addition of Sue Sutton-Jones as Vice President of Regulatory Affairs and Quality Assurance. Ms. Sutton-Jones comes to MBio from ConMed Livatec, a global leader in the fields of arthroscopy, endoscopic medical video systems and powered surgical instruments. Prior to this, Sue was with OraSure Technologies, Inc., where she led the regulatory efforts for multiple products, including rapid tests for HIV and hepatitis C, and was responsible for the initiative that resulted in obtaining US FDA approval on the Premarket Approval Application (PMA) for the first over-the-counter HIV rapid test. Ms. Sutton-Jones is experienced in building high-performance regulatory and quality teams with international scope and impact.

Commenting on Sue joining MBio, Christopher Myatt, CEO and Founder, noted, “We are pleased to have Sue join the MBio team. She brings a wealth of experience to our mission to increase access to quality healthcare through innovative and low cost point of care diagnostics.”

About MBio:

MBio Diagnostics, Inc. (www.mbiodx.com) is a privately held diagnostics and life sciences company based in Boulder, CO. MBio Diagnostics is increasing access to quality healthcare by delivering innovative and low cost point-of-care (POC) diagnostics. The MBio System is initially being commercialized to manage the treatment of HIV patients from a single drop of blood. The MBio elegant detection system is being developed for a broad menu of applications including multiplex assays and cellular analysis.